|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
A Phase 1 Study of AGENT-797 to treat moderate to severe acute respiratory syndrome in COVID-19 patients.
Description: Number and severity of adverse events (AEs)Measure: Incidence of Treatment-Emergent Adverse Events Time: 6 months
Description: Number of Dose Limiting ToxicitiesMeasure: Number of Dose Limiting Toxicities Time: 6 months
Description: Time to extubation. Assessment of ventilator-free days. Oxygenation improvement as per Berlin definition (ARDS 2012). Supportive interventions used (e.g. use of prone ventilation, paralytics, pulmonary vasodilators, and other interventions affecting oxygenation).Measure: To assess time to improvement in pulmonary function. Time: 30 days
Description: Decay in quantitative viral burden from upper and lower respiratory tract samples collected.Measure: Amount of virus detected in respiratory tract samples. Time: 30 days
Description: Persistence of allogeneic invariant natural killer T cells (iNKT) non-transduced cells.Measure: To assess longevity of agenT-797 infusion. Time: 30 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports